Beijing, China

Xiaobo Hao

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Innovations and Contributions of Inventor Xiaobo Hao

Introduction

Xiaobo Hao is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibodies. With a total of three patents to his name, Hao's work has the potential to impact various medical applications.

Latest Patents

One of Xiaobo Hao's latest patents is titled "Anti-IL-4R antibody and use thereof." This patent discloses an antibody or an antigen-binding portion that binds to human IL-4R. It includes a polynucleotide encoding the antibody, a vector comprising the polynucleotide, and a method for preparing and purifying the antibody. The use of this antibody or its antigen-binding portion is also detailed in the application. Another significant patent is for a "Bispecific antibody against rabies virus, and application thereof." This patent provides a bispecific antibody that targets different epitopes of the G protein of the rabies virus, demonstrating rabies virus neutralization activity.

Career Highlights

Xiaobo Hao has worked with notable companies in the biotechnology sector, including Beijing Wisdomab Biotechnology Co., Ltd. and Genrix (Shanghai) Biopharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in antibody development and biopharmaceutical innovations.

Collaborations

Hao has collaborated with esteemed colleagues, including Zhigang Liu and Yulan Liu. These partnerships have likely enhanced his research and development efforts in the field of biotechnology.

Conclusion

Xiaobo Hao's innovative work in antibody development showcases his significant contributions to biotechnology. His patents reflect a commitment to advancing medical science and improving therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…